Patrick Cobb

1.7k total citations
43 papers, 476 citations indexed

About

Patrick Cobb is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Patrick Cobb has authored 43 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Patrick Cobb's work include Cancer Treatment and Pharmacology (12 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Patrick Cobb is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Patrick Cobb collaborates with scholars based in United States, Australia and United Kingdom. Patrick Cobb's co-authors include William N. Dudley, Christine Miaskowski, Susan L. Beck, Ginette A. Pepper, Jeannine M. Brant, Lee S. Schwartzberg, C. Frederick LeMaistre, Daniel D. Von Hoff, Bradley D. Hunter and John R. Eckardt and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Patrick Cobb

42 papers receiving 460 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick Cobb United States 14 301 105 96 66 50 43 476
Lee Schwartzberg United States 8 333 1.1× 133 1.3× 113 1.2× 77 1.2× 40 0.8× 17 603
Tallal Younis Canada 15 331 1.1× 118 1.1× 106 1.1× 80 1.2× 24 0.5× 34 577
Cindi Bedell United States 9 212 0.7× 65 0.6× 174 1.8× 46 0.7× 31 0.6× 14 401
Jo Ann Davis United States 14 203 0.7× 76 0.7× 188 2.0× 80 1.2× 25 0.5× 30 852
Radhika Gogoi United States 13 176 0.6× 52 0.5× 185 1.9× 38 0.6× 43 0.9× 51 554
S. Verma Canada 13 217 0.7× 62 0.6× 70 0.7× 160 2.4× 50 1.0× 20 450
Serena Wong United States 18 272 0.9× 127 1.2× 168 1.8× 42 0.6× 18 0.4× 47 786
Robert F. Asbury United States 16 273 0.9× 150 1.4× 96 1.0× 54 0.8× 33 0.7× 44 653
Henry J. Durivage United States 12 226 0.8× 68 0.6× 218 2.3× 29 0.4× 22 0.4× 21 458
Nadeem Bilani United States 10 161 0.5× 74 0.7× 82 0.9× 34 0.5× 16 0.3× 38 364

Countries citing papers authored by Patrick Cobb

Since Specialization
Citations

This map shows the geographic impact of Patrick Cobb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Cobb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Cobb more than expected).

Fields of papers citing papers by Patrick Cobb

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Cobb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Cobb. The network helps show where Patrick Cobb may publish in the future.

Co-authorship network of co-authors of Patrick Cobb

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Cobb. A scholar is included among the top collaborators of Patrick Cobb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Cobb. Patrick Cobb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hoffmann, Marc, et al.. (2023). Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplantation and Cellular Therapy. 29(7). 440–448. 35 indexed citations
3.
Dumbrava, Ecaterina E., Christopher T. Chen, Gregory M. Coté, et al.. (2023). Abstract B034: A phase 2 basket study of the oral MDM2 inhibitor milademetan for MDM2-amplified advanced solid tumors (MANTRA-2). Molecular Cancer Therapeutics. 22(12_Supplement). B034–B034. 1 indexed citations
4.
Schwartzberg, Lee S., Michael S. Broder, Sikander Ailawadhi, et al.. (2022). Impact of early detection on cancer curability: A modified Delphi panel study. PLoS ONE. 17(12). e0279227–e0279227. 6 indexed citations
5.
6.
Niederwieser, Dietger, Caroline Hamm, Patrick Cobb, et al.. (2020). Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product. Targeted Oncology. 15(6). 807–807. 1 indexed citations
7.
Niederwieser, Dietger, Caroline Hamm, Patrick Cobb, et al.. (2020). Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product. Targeted Oncology. 15(5). 599–611. 14 indexed citations
8.
Niederwieser, Dietger, Caroline Hamm, Patrick Cobb, et al.. (2020). Efficacy and safety of ABP 798 compared with rituximab: Results from the comparative clinical study in patients with non-Hodgkin’s.. Journal of Clinical Oncology. 38(15_suppl). 8044–8044. 1 indexed citations
9.
Choueiri, Toni K., David I. Quinn, Tian Zhang, et al.. (2018). KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.. Journal of Clinical Oncology. 36(15_suppl). TPS4599–TPS4599. 16 indexed citations
10.
Patt, Debra A., et al.. (2012). Thoughts and recommendations on cancer care site of service. Community Oncology. 9(12). 382–388. 1 indexed citations
11.
Brant, Jeannine M., Susan L. Beck, William N. Dudley, et al.. (2011). Symptom trajectories during chemotherapy in outpatients with lung cancer colorectal cancer, or lymphoma. European Journal of Oncology Nursing. 15(5). 470–477. 42 indexed citations
12.
Brant, Jeannine M., Susan L. Beck, William N. Dudley, et al.. (2010). Symptom Trajectories in Posttreatment Cancer Survivors. Cancer Nursing. 34(1). 67–77. 36 indexed citations
13.
Schwartzberg, Lee S., Patrick Cobb, Mark S. Walker, Edward J. Stepanski, & Arthur C. Houts. (2009). Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer. Supportive Care in Cancer. 17(8). 1081–1088. 10 indexed citations
14.
Schwartzberg, Lee S., Patrick Cobb, Frank M. Senecal, et al.. (2009). Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer. The Breast. 18(2). 78–83. 12 indexed citations
15.
Doroshow, James H., Sheryl McCoy, John S. Macdonald, et al.. (2006). Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study. Investigational New Drugs. 24(6). 537–542. 10 indexed citations
16.
Villalona‐Calero, Miguel A., Thierry Petit, John G. Kuhn, et al.. (1999). A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.. PubMed. 5(11). 3369–78. 2 indexed citations
17.
Bowen, Karen, et al.. (1995). Mixed-Lineage Acute Myeloid Leukemia Associated with a Suprasellar Dysgerminoma. American Journal of Clinical Oncology. 18(1). 83–86. 5 indexed citations
18.
Burris, Howard A., Ahmad Awada, John G. Kuhn, et al.. (1994). Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anti-Cancer Drugs. 5(4). 394–402. 40 indexed citations
19.
Cobb, Patrick, Donna Degen, Gary M. Clark, et al.. (1994). Activity of DMP 840, a New Bis-naphthalimide, on Primary Human Tumor Colony-Forming Units. JNCI Journal of the National Cancer Institute. 86(19). 1462–1465. 13 indexed citations
20.
Cobb, Patrick, Kathleen A. Havlin, John G. Kuhn, et al.. (1991). Phase I Evaluation of Crisnatol (BWA770U Mesylate) on a Monthly Extended Infusion Schedule. PubMed. 7(2). 85–91. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lee Schwartzberg Breakdown of academic impact, for papers by Tallal Younis Breakdown of academic impact, for papers by Cindi Bedell Breakdown of academic impact, for papers by Jo Ann Davis Breakdown of academic impact, for papers by Radhika Gogoi Breakdown of academic impact, for papers by S. Verma Breakdown of academic impact, for papers by Serena Wong Breakdown of academic impact, for papers by Robert F. Asbury Breakdown of academic impact, for papers by Henry J. Durivage Breakdown of academic impact, for papers by Nadeem Bilani
Rankless by CCL
2026